First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson’s
The first patient has been dosed in a clinical trial testing Annovis Bio’s buntanetap as an oral therapy for…
Articles by Margarida Maia, PhD
Excessive Drooling as Parkinson’s Advances Not Tied to DBS in Study
Deep brain stimulation (DBS) may not put people with advanced Parkinson’s disease at a greater risk of excessive drooling,…
Genetic Mutations May Affect Parkinson’s Progression
Certain genetic mutations may help determine the length of survival in Parkinson’s disease patients, according to findings by a…
High RAS Antibody Levels May Drive Disease, But Medicines Exist
Antibodies against certain components of the renin-angiotensin system (RAS), which helps to control blood pressure, are present at higher levels…
‘Off’ Episodes May Affect 1 in 3 Patients Come Bedtime, Trials Find
About 1 in 3 Parkinson’s disease patients in two Phase 3 trials experienced an “off” episode before going to sleep,…
Stem Cells, Turned Into Neurons, Restore Motor Function in Rats
Stem cells in the lab were turned into nerve cells (neurons) that can make dopamine — the chemical that is…
Study of Oral UCB0599 Enrolling Patients With Mild Symptoms
UCB, a global pharmaceutical company, is looking for men and women with early-stage Parkinson’s disease who want to…
AbbVie Files for FDA Approval of ABBV-951 Levodopa Infusion
AbbVie has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa), its…
MJFF Grant Moves Potential Oral Therapy, ASN51, Into Early Testing
A research grant from The Michael J. Fox Foundation (MJFF) will allow Asceneuron to advance work on ASN51, a…
Dose-ranging Study of Cannabinoid Mixtures for Rodents Set To Begin
Gb Sciences is initiating a dose-ranging study of its investigational cannabinoid-based formulations in a rodent model of Parkinson’s…